Post-earnings recap
Reported
Thu, Jul 30, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Corvus Pharmaceuticals reported a loss of $0.36 per share, which was below expectations, but the stock still rose by 2.64%. This increase may reflect investor optimism or a response to other market factors, despite the earnings miss. The lack of revenue and guidance updates leaves uncertainty about the company's future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.36 | N/A | -22.03% |
| Revenue | $0 | N/A | N/A |
No transcript is on record, and the analysis is based solely on numerical results.